Group 1 - The report initiates coverage on Dongpeng Beverage (09980) with a rating of "Overweight" [1] - The core view is that Dongpeng's market share growth in China will enable it to continue outperforming its peers [1] - The preliminary earnings forecast for 2025 indicates an average revenue growth rate of 25% and a core net profit growth rate of 16% for Q4 [1] Group 2 - For 2026, the expected year-on-year growth rates for energy drinks, sports drinks, and other products are projected to be 15%, 42%, and 50% respectively, supporting a total revenue growth of 22% [1] - The target price set for Dongpeng Beverage is HKD 315 [1]

Investment Rating - The report assigns an "Overweight" rating to the company [1] Core Insights - Morgan Stanley has revised its revenue and profit forecasts for the company for the years 2025 to 2027 down by 1% and approximately 3% respectively [1] - The revenue forecast for the last quarter of the previous year has been adjusted from a high single-digit growth to a mid-single-digit growth, primarily due to macroeconomic slowdown and weak dining demand [1] - The firm anticipates that gradual economic recovery and pipeline expansion will support the company in achieving high single-digit revenue and profit growth in 2026 and 2027 [1] - The target price for the company has been slightly reduced from HKD 41 to HKD 40 [1]

Investment Rating - The report assigns an "Overweight" rating to Sanhua Intelligent Control (02050) and raises the target price to HKD 45 from HKD 42, while also increasing the target price for its A-shares (002050.SH) to RMB 64 from RMB 49 [1] Core Insights - The report highlights that the management's latest guidance and the full-year performance forecast exceeded expectations, prompting the upward revision of target prices [1] - JPMorgan has increased its earnings estimates for Sanhua Intelligent Control by 5% for the years 2025 to 2027, reflecting the accelerated opportunities in the humanoid robotics sector [1] - The firm believes that the company's robust performance, combined with multiple favorable factors expected this year, presents an ideal buying opportunity for both A-shares and H-shares during market pullbacks [1]

Investment Rating - The investment rating for the company is "Buy" (first coverage) [5] Core Insights - The report highlights significant profit growth, with the life insurance new business value (NBV) continuing to grow at a high rate [5] - In Q3 2025, the group's net profit attributable to shareholders increased by 45.4% year-on-year to 64.8 billion yuan, driven by a 15.2% increase in operating profit attributable to shareholders [6] - The life insurance NBV growth rate improved from 39.8% in the mid-year report to 46.2% in the Q3 report, indicating strong performance in the life insurance segment [6][8] Summary by Relevant Sections Market Performance - Closing price as of February 25, 2026, was 71.15 HKD, with a market capitalization of approximately 1,288.36 billion HKD [3] Financial Performance - In Q3 2025, the life insurance, property insurance, and banking segments' operating profit attributable to shareholders grew by 0.6%, 26.2%, and -2.8% year-on-year, respectively [7] - The overall performance of the company is strong, with a significant increase in net assets and a reduction in losses in the asset management segment [7] Life Insurance Business - The life insurance NBV growth rate for the first three quarters of 2025 expanded to 46.2%, with agent and bancassurance channels showing growth rates of 23.3% and 170.9%, respectively [8] - The company's strategy of combining products with medical and elderly care services is expected to drive further growth in the agent channel [8] Investment Situation - The comprehensive investment return rate for the first three quarters of 2025 increased by 1 percentage point to 5.4% compared to the same period in 2024, attributed to a significant increase in equity assets [9] - The core solvency ratio for life insurance decreased by 32.5 percentage points to 135% due to increased capital requirements [9][10] Profit Forecast and Valuation - The forecasted net profit for the company for 2025, 2026, and 2027 is 135.2 billion, 173.0 billion, and 202.2 billion yuan, respectively, with year-on-year growth rates of 6.77%, 27.95%, and 16.93% [10] - The estimated intrinsic value per share for 2025, 2026, and 2027 is projected to be 84.78, 92.20, and 98.87 yuan, respectively, with a current price-to-earnings valuation of 0.74, 0.68, and 0.64 times [10]

Investment Rating - The report assigns an initial investment rating of "Buy" for the company, highlighting its potential for resource empowerment and stable dividend growth [5][7]. Core Views - The company is positioned as the only natural gas terminal sales platform under PetroChina, having transitioned from exploration and development to focus on downstream natural gas sales and comprehensive utilization since 2008 [6][14]. - The company has a strong cash position with a total cash and deposits of 42.875 billion RMB as of June 2025, and a projected free cash flow exceeding 9 billion RMB in 2024, indicating potential for increased dividends [6][29]. - The company is expected to maintain high gas sales growth, with retail gas volume growth rates projected at 3.7%, 4.4%, and 4.8% for 2025-2027 [8][49]. Summary by Relevant Sections Financial Performance - Revenue projections for the company are as follows: 177.35 billion RMB in 2023, 187.05 billion RMB in 2024, and reaching 207.06 billion RMB by 2027, with a compound annual growth rate (CAGR) of approximately 3.6% [5][6]. - The net profit attributable to shareholders is forecasted to be 5.68 billion RMB in 2023, increasing to 6.61 billion RMB by 2027, reflecting a steady growth trajectory [5][6]. - The earnings per share (EPS) are expected to rise from 0.66 RMB in 2023 to 0.76 RMB in 2027, with a price-to-earnings (P/E) ratio projected at 10-11 times [5][7]. Market Position and Strategy - The company has a leading position in acquiring new city gas projects, with 293 projects as of June 2025, despite a general slowdown in the industry [36][37]. - The company benefits from a strong resource guarantee from its parent company, PetroChina, which enhances its ability to supply industrial users and maintain competitive pricing [9][43]. - The company operates two LNG receiving stations and is constructing a third, which is expected to contribute to revenue growth upon completion in 2027 [77][80]. Risk Management and Stability - The company has a lower debt ratio of 35.3% as of June 2025, which is below that of its peers, indicating a strong financial position [23][29]. - The company’s gas sales structure is heavily weighted towards industrial users, which allows for better price transmission and stability in profit margins [56][62]. - The company has a robust dividend policy, planning a payout ratio of 45% in 2025, with a current dividend yield of 4.3% based on the latest stock price [7][29].

Investment Rating - The investment rating for the company is "Buy" [7] Core Insights - The company, known as a leading ODM in intimate apparel, maintains its industry leadership through differentiated technology and is expanding into sportswear categories. In FY26H1, the company reported a revenue of HK$3.84 billion, a year-on-year decrease of 3.4%, with intimate apparel contributing HK$2.1 billion (down 6.6%, accounting for 54.7%) and sports products generating HK$1.51 billion (up 13.4%, accounting for 39.2%). The net profit attributable to shareholders was HK$140 million, reflecting a significant year-on-year increase of 114.3% [1][5] Summary by Sections Company Overview - The company is recognized as a global leader in ODM for intimate apparel, focusing on differentiated innovation to expand its sportswear category [1][2] Financial Performance - In FY26H1, the company achieved a revenue of HK$3.84 billion, with a notable increase in sports product revenue by 13.4% to HK$1.51 billion, while intimate apparel revenue decreased by 6.6% to HK$2.1 billion. The net profit attributable to shareholders reached HK$140 million, marking a 114.3% increase year-on-year [1][5] Technological Innovation - The company's bonding technology, which replaces traditional sewing methods, has been validated in the market, enhancing comfort and gaining recognition from key domestic and international brands. The revenue from bonding functional apparel increased by 40% to HK$700 million in FY26H1, contributing to the growth of the sports segment [2] Brand Performance - The company holds a 49% stake in Victoria's Secret China, which has shown strong performance. The return of the Victoria's Secret Fashion Show is expected to enhance brand visibility, with FY26Q1-3 showing a revenue increase of 3.9% and net profit growth of 17.9%. In FY26H1, Victoria's Secret China achieved a revenue of HK$1.22 billion (up 37.3%) and a net profit of HK$130 million (up 645%) [3] Operational Developments - The relocation of the production base from Shenzhen to Zhaoqing is nearing completion, with a reduction in one-time employee compensation costs. The company plans to reduce debt over the next three years, which is expected to lower interest expenses significantly [4] Profit Forecast and Valuation - The company is projected to achieve net profits of HK$290 million, HK$400 million, and HK$610 million for FY25, FY26, and FY27, respectively, representing year-on-year growth rates of 97.7%, 41.5%, and 50.5%. The price-to-earnings ratio is expected to be 10.7, 7.5, and 5.0 for the same years, maintaining a "Buy" rating [5]

Investment Rating - The report assigns a "Buy" rating for China Life Insurance, indicating a positive outlook based on strong individual insurance sales capabilities and good investment performance [5]. Core Insights - China Life's Q3 revenue and net profit attributable to shareholders grew by 54.8% and 91.5% year-on-year, reaching CNY 298.7 billion and CNY 126.9 billion, respectively, which boosted the year-to-date revenue and net profit growth rates to 25.9% and 60.5% [5][10]. - The company's net assets attributable to shareholders increased by 22.8% to CNY 625.8 billion by the end of Q3, outperforming peers [8]. - The new business value (NBV) grew by 41.8% year-on-year, and the total investment return rate increased by 104 basis points to 6.42% [5][7]. Financial Performance - For the first three quarters of 2025, total investment income rose by 41% to CNY 368.6 billion, with a total investment return rate of 6.42% [7][10]. - The net profit for Q3 2025 reached CNY 126.9 billion, a significant increase from CNY 66.2 billion in Q3 2024, driven by reduced insurance service costs and strong new policy sales [8][10]. - The company has shown a strong improvement in new policy sales, with a year-on-year growth rate of 52.5% in Q3 2025 [8]. Earnings Forecast and Valuation - The report forecasts China Life's net profit for 2025-2027 to be CNY 153.0 billion, CNY 174.2 billion, and CNY 196.1 billion, with year-on-year growth rates of 43%, 14%, and 13% respectively [10]. - The estimated embedded value per share for 2025-2027 is projected to be CNY 56.0, CNY 61.7, and CNY 67.3, with current price-to-embedded value (P/EV) ratios of 0.55, 0.50, and 0.46 [10].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected outperformance of over 15% relative to the Hang Seng Index [6][9]. Core Insights - The international version of the self-developed life simulation game "Heart Town" launched on January 8, achieving over 12 million downloads globally, ranking 11th in the January mobile game download chart, with estimated revenue of 60 million RMB for the month [2]. - The company reported a 39% year-on-year revenue growth to 3.08 billion RMB for the first half of 2025, with adjusted profit increasing by 206% to 850 million RMB, exceeding market expectations [3]. - TapTap's revenue grew by 38% year-on-year to 1.01 billion RMB, with a gross margin increase of 1.1 percentage points to 83.6%, despite a slight decline in active users [4]. - The company initiated a share buyback plan in January, aiming to repurchase up to 400 million RMB worth of shares, reflecting confidence in its business outlook [5]. Summary by Sections Game Performance - "Heart Town" has shown high market acceptance, with significant revenue contributions expected for future operations and growth in 2026 [2]. - The company has a stable user base for its evergreen games, with notable revenue growth from "Ragnarok M: Origin" and plans for continued R&D investment [3]. Financial Performance - The company’s revenue and adjusted profit are projected to grow at a compound annual growth rate (CAGR) of 17% and 33% respectively from 2024 to 2027, with an expected adjusted profit of 1.62 billion RMB in 2025 [5]. Market Position - The current share price is 77.80 RMB, with a target price of 89.00 RMB, indicating a potential upside of 14.4% [6].

息差回升及财富优异推动盈利向好 | 华泰研究 | | | 年报点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2026 年 | 2 月 | 25 日│中国香港 | 区域性银行 | 目标价(港币): | 166.07 | 经调口径下，汇丰控股 25A 营收同比+5.1%，税前利润同比+7.1%，增速较 25Q1-3 分别+0.3pct、+2.6pct。2025 年经调 ROTE 为 17.2%，同比 2024 年+1.6pct，主因净利息收入增长及财富管理收入增加。董事会已通过派发 第四次股息每股0.45美元，2025年每股合计派息0.75美元。公司指引2026、 2027 及 2028 年平均 ROTE 达到 17%甚至更高，争取 28 年营收同比增速 达 5%。鉴于公司组织架构调整提升运营效率，维持"买入"评级。 证券研究报告 NII 环比提升，指引 26 年最少达 450 亿美元 汇丰控股 (5 HK) 港股通 公司 2025 年银行业务净利息收益同比+0.2%至 441 亿美元，其中 25Q4 单 季环比 Q3+6.1%，主要受 ...